" class="no-js "lang="en-US"> Gene-Editing Archives - Medtech Alert
Tuesday, December 05, 2023

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies

Applied StemCell and the California Institute for Regenerative Medicine (CIRM) have partnered as Industry Resource […]

HuidaGene Therapeutics' Novel DNA Gene-Editing System Cas12i Patent Granted by USPTO

HuidaGene Therapeutics, a clinical-stage company focusing on developing gene editing tools and gene therapies, today […]

Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research for DMD

Precision BioSciences, a clinical-stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and […]

Synthego Launches Express Cell Pools for Faster, More Efficient Genome Editing

Synthego, a leading provider of genome engineering solutions, has announced the launch of Express Knockout […]

Vertex and CRISPR Therapeutics Announce Licensing Agreement

Vertex Pharmaceuticals and CRISPR Therapeutics today announced that they have entered into a new non-exclusive […]

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform

Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further […]

Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology

Chroma Medicine, a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion […]

New AI Tool Makes Speedy Gene Editing Possible

An artificial intelligence (AI) program may enable the first simple production of customizable proteins called […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more